Treatment of branch-duct intraductal papillary mucinous neoplasms of the pancreas: state of the art

Updates Surg. 2016 Sep;68(3):265-271. doi: 10.1007/s13304-016-0386-8. Epub 2016 Aug 8.

Abstract

The diagnosis of branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) has been dramatically increased. BD-IPMNs are frequently discovered as incidental findings in asymptomatic individuals, mainly in elderly patients. An accurate evaluation of BD-IPMNs with high-resolution imaging techniques and endoscopic ultrasound is necessary. Patients with high-risk stigmata (HRS, obstructive jaundice, enhanced solid component) should undergo resection. Patients with worrisome features (WF, cyst size ≥3 cm, thickened enhanced cyst walls, non-enhanced mural nodules, and clinical acute pancreatitis) may undergo either a strict surveillance based on patients' characteristics (age, comorbidities) or surgical resection. Non-operative management is indicated for BD-IPMNs without HRS and WF. Patients with BD-IPMN who do not undergo resection may develop malignant change over time as well as IPMN-distinct pancreatic cancer. However, non-operative management of BD-IPMNs lacking WF and HRS is safe and the risk of malignant degeneration seems relatively low. The optimal surveillance protocol is currently unclear.

Keywords: Branch-duct; High-risk stigmata; Intraductal papillary mucinous neoplasms; Surgery; Surveillance; Worrisome features.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma, Mucinous / diagnosis
  • Adenocarcinoma, Mucinous / surgery*
  • Carcinoma, Pancreatic Ductal / diagnosis
  • Carcinoma, Pancreatic Ductal / surgery*
  • Endosonography
  • Humans
  • Pancreatic Ducts / diagnostic imaging
  • Pancreatic Ducts / surgery
  • Pancreatic Neoplasms / diagnosis
  • Pancreatic Neoplasms / surgery*
  • Treatment Outcome